Michal Pawlak
About Michal Pawlak
Michal Pawlak is a Senior Bioinformatician at ORIC Pharmaceuticals Inc. and an Assistant Professor at IHiT Instytut Hematologii i Transfuzjologii in Warsaw, Poland, with a strong background in embryonic development and metabolic diseases research.
Work at ORIC Pharmaceuticals
Michal Pawlak has been employed at ORIC Pharmaceuticals Inc. as a Senior Bioinformatician since 2021. In this role, he contributes to the company's research initiatives, focusing on bioinformatics applications in drug development and cancer genomics. His expertise supports the advancement of innovative therapies aimed at treating various cancers.
Education and Expertise
Michal Pawlak studied at multiple prestigious institutions, achieving a Doctor of Philosophy (PhD) in Molecular Biology, with a focus on endocrinology and metabolic diseases, from Université du Droit et de la Santé (Lille II) between 2009 and 2013. He also obtained a Master of Science in Biotechnology from Universiteit Gent in 2009. Additionally, he achieved habilitation in medical sciences in 2021, further solidifying his expertise in the field.
Background
Pawlak has a diverse professional background, having worked in various research and academic positions. He served as a Postdoctoral Fellow and Project Leader at the International Institute of Molecular and Cell Biology in Warsaw from 2014 to 2018. He also held roles at Inserm and RIKEN, gaining international experience in molecular biology research. His career includes founding get2omics, a venture focused on bioinformatics solutions, from 2019 to 2021.
Achievements
Since March 2022, Michal Pawlak has led the Laboratory of Blood Cancer Genomics at IHiT Instytut Hematologii i Transfuzjologii, where he focuses on innovative research in cancer genomics. His extensive experience in metabolic diseases research has contributed to a deeper understanding of the molecular mechanisms underlying these conditions. He also holds the position of Group Leader at IHiT, where he continues to advance research in hematology.